S. Karger AG

SHERPA: Unknown

People

  1. Levine
    Levine
  2. Van Den Brink
    Van Den Brink
  3. Lowe
    Lowe
  4. Abdel-Wahab
    Abdel-Wahab
  5. Koche
    Koche
  6. Yang
    Yang
  7. De Stanchina
    De Stanchina
  8. Joseph
    Joseph
  9. Offit
    Offit
  10. Rampal
    Rampal

Groups

  1. Center for Hematologic Malignancies (20)
  2. Executive Committee, Center for Hematologic Malignancies (20)
  3. GSK Faculty (19)
  4. Department of Medicine (17)
  5. Hematologic Malignancies, Division of (16)
  6. Sloan Kettering Institute Faculty (10)
  7. Human Oncology and Pathogenesis Program (9)
  8. Adult Leukemia (7)
  9. Immunology Program Faculty (6)
  10. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (5)
Search Within
  1. "Executive Committee, Center for Hematologic Malignancies"
Formats
  1. Meeting Abstract (17)
  2. Journal Article (3)
Groups
  1. Center for Hematologic Malignancies (20)
  2. Executive Committee, Center for Hematologic Malignancies (20)
  3. GSK Faculty (19)
  4. Department of Medicine (17)
  5. Hematologic Malignancies, Division of (16)
  6. Sloan Kettering Institute Faculty (10)

More Groups

People
  1. Ross Levine (7)
  2. Marcel Van Den Brink (6)
  3. Scott Lowe (4)
  4. Omar Abdel-Wahab (3)
  5. Barry Kappel (2)
  6. Christoph Miething (2)

More People

Years
  1. 2022 (1)
  2. 2020 (3)
  3. 2019 (1)
  4. 2017 (2)
  5. 2016 (1)
  6. 2015 (1)

More Years

Publications
  1. Oncology Research and Treatment (10)
  2. Acta Haematologica (5)
  3. Onkologie (5)

Results (20)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Resistenz auf typ II JAK2 inhibition via persistente MAPK aktivierung kann durch MEK inhibition überwunden werden
    Meeting Abstract

    Codilupi, T.; Szybinski, J.; Brkic, S.; Stivala, S.; Yang, J. L.; Wicki, A.; Ghosh, N.; Passweg, J.; Dirnhofer, S.; Levine, R. L.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Combined JAK2 and ERK1/2 kinase inhibition as a novel therapeutic approach in myeloproliferative neoplasms
    Meeting Abstract

    Brkic, S.; Stivala, S.; Santopolo, A.; Jungius, S.; Passweg, J. R.; Tsakiris, D.; Dirnhofer, S.; Levine, R. L.; Meyer, S. C.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Resistance to type II JAK2 inhibition in MPN is dependent on MEK-ERK activation and is targetable
    Meeting Abstract

    Codilupi, T.; Szybinski, J.; Wicki, A.; Yang, J. L.; Ghosh, N.; Passweg, J.; Tsakiris, D.; Levine, R. L.; Koche, R.; Meyer, S. C.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Dual genetic targeting of ERK1 and ERK2 abrogates the competitive potential of the myeloproliferative neoplasm clone
    Meeting Abstract

    Stivala, S.; Brkic, S.; Santopolo, A.; Dirnhofer, S.; Passweg, J.; Tsakiris, D.; Neel, B.; Levine, R.; Meyer, S.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Tumor cell-intrinsic activity of the RNA receptor RIG-I promotes checkpoint inhibitor-mediated anticancer immunity
    Meeting Abstract

    Heidegger, S.; Wintges, A.; Stritzke, F.; Bek, S.; Steiger, K.; Winter, C.; Rad, R.; van den Brink, M. R. M.; Ruland, J.; Bassermann, F.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Anti-CTLA-4 checkpoint inhibitormediated anticancer immunity relies on tumor-intrinsic RIG-I signaling
    Meeting Abstract

    Heidegger, S.; Wintges, A.; Bek, S.; Schmickl, M.; Steiger, K.; Koenig, P. A.; Ruland, J.; van den Brink, M. R. M.; Peschel, C.; Haas, T.; more...
    Oncology Research and Treatment (2017)

    Fulltext@MSK | Save
  • Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: Full results after extended follow-up of the multicohort, multicenter phase 2 CheckMate 205 trial
    Meeting Abstract

    Jäger, U.; Engert, A.; Fanale, M.; Santoro, A.; Armand, P.; Ansell, S.; Zinzani, P. L.; Timmerman, J. M.; Collins, G. P.; Ramchandren, R.; more...
    Oncology Research and Treatment (2017)

    Fulltext@MSK | Save
  • Activation of the cytosolic RNA receptor RIG-I in tumor and immune cells triggers efficient anti-tumor immunity and synergizes with checkpoint blockade
    Meeting Abstract

    Heidegger, S.; Wintges, A.; Kreppel, D.; Bscheider, M.; Bek, S.; Fischer, J.; Schmickl, M.; Ruland, J.; van den Brink, M.; Peschel, C.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • Treatment of refractory hairy cell leukemia by BRAF-inhibition
    Meeting Abstract

    Dietrich, S.; Pircher, A.; Andrulis, M. A.; Peyrade, F.; Wendtner, C. M.; Gaehler, A.; Follows, G.; Dyer, M.; Elter, T.; Zeiser, R.; more...
    Oncology Research and Treatment (2015)

    Fulltext@MSK | Save
  • Prevention of minimal residual disease in Ph plus ALL
    Meeting Abstract

    Appelmann, I.; Rillahan, C. D.; de Stanchina, E.; Carbonetti, G.; Chen, C.; Lowe, S. W.; Sherr, C. J.
    Oncology Research and Treatment (2014)

    Fulltext@MSK | Save